X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

STAB

Closed

Statera Biopharma Inc

0.0001
0.0000 (0.00%)
Last Update: 01 Jul 2025 16:30:00
Yesterday: 0.0001
Day's Range: 0.0001 - 0.0001
Send
When Written:
 
0.01675
Statera Biopharma Inc. is a clinical-stage biotechnology company that focuses on developing small molecule therapies for the treatment of serious diseases. The company's lead product candidate is ST-101, a selective cannabinoid receptor type 1 (CB1) inverse agonist that is being developed for the treatment of pruritus (itching) associated with various conditions, including chronic liver diseases, atopic dermatitis, and psoriasis.

Statera Biopharma was founded in 2016 and is headquartered in San Diego, California. The company's management team has extensive experience in drug development and has worked at companies such as Pfizer, Merck, and Eli Lilly.

In addition to ST-101, Statera Biopharma is also developing other small molecule therapies, including ST-102 for the treatment of nonalcoholic steatohepatitis (NASH) and ST-104 for the treatment of chronic obstructive pulmonary disease (COPD).

The company has partnerships with academic institutions and research organizations to advance its drug development programs. Statera Biopharma is also actively seeking partnerships with pharmaceutical companies to further develop and commercialize its product candidates.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X